DRC3: A Protein Targeted for Vast Diseases (G83450)

Target Name: DRC3

NCBI ID: G83450

DRC3

DRC3: A Protein Targeted for Vast Diseases

DRC3 (DRC3_HUMAN), also known as human DRC3, is a protein that is expressed in human tissues and is known for its role in the development and progression of various diseases, including cancer. The protein is a key regulator of the cell cycle and has been shown to play a role in the regulation of cell growth, apoptosis, and angiogenesis.

Recent studies have identified DRC3 as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The protein is also a potential biomarker for disease diagnosis and monitoring.

One of the key functions of DRC3 is its role in the regulation of the cell cycle. The protein helps to control the length of the cell cycle by regulating the activity of several key genes that are involved in the cell cycle. This regulation is critical for the growth and development of tissues and organs, and is also important for the regulation of cancer growth.

In addition to its role in cell cycle regulation, DRC3 is also involved in the regulation of apoptosis, which is the process by which cells die and are removed from the body. The protein helps to regulate the apoptosis-associated protein (AP-120) and has been shown to play a role in the regulation of cell life cycle.

DRC3 has also been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body. The protein helps to control the growth and differentiation of blood vessels and has been shown to play a role in the development of atherosclerosis, which is the leading cause of heart disease.

The potential drug targets for DRC3 are vast, and include a variety of diseases and conditions. In addition to cancer and neurodegenerative diseases, DRC3 has also been shown to be involved in the regulation of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

One of the potential benefits of targeting DRC3 is its potential to be a once-daily drug, as it is expressed in most tissues and can be easily detected in the body using techniques such as Western blotting. Additionally, DRC3 is a protein that is widely expressed in human tissues and is not highly expressed in any particular tissue, which could make it an attractive target for small molecules that can be easily synthesized and administered once daily.

In conclusion, DRC3 is a protein that has the potential to be a drug target for a variety of diseases and conditions. Its role in cell cycle regulation, apoptosis, and angiogenesis makes it an attractive target for small molecules that can be easily administered once daily. Further research is needed to fully understand the mechanisms of DRC3's role in disease and to develop safe and effective drugs that target this protein.

Protein Name: Dynein Regulatory Complex Subunit 3

Functions: Component of the nexin-dynein regulatory complex (N-DRC) a key regulator of ciliary/flagellar motility which maintains the alignment and integrity of the distal axoneme and regulates microtubule sliding in motile axonemes

The "DRC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DRC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets